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Summary
Objectives: To determine (1) if interleukin-1 alpha (IL-1a), insulin like growth factor I (IGF-I), and transforming growth factor-beta 1 (TGF-b1)
regulate proteoglycan 4 (PRG4) metabolism in articular cartilage, in terms of chondrocytes expressing PRG4 and PRG4 bound at the articular
surface, and (2) if these features of cartilage PRG4 metabolism correlate with its secretion.
Methods: Articular cartilage explants were harvested and cultured for 6 days with or without 10% fetal bovine serum (FBS), alone, or with the
addition of 10 ng/ml IL-1a, 300 ng/ml IGF-I, or 10 ng/ml TGF-b1. PRG4 expression by chondrocytes in the cartilage disks was assessed by
immunohistochemistry (IHC). PRG4 bound to the articular surface of disks was quantiﬁed by extraction and enzyme-linked immunosorbent
assay (ELISA). PRG4 secreted into culture medium was quantiﬁed by ELISA and characterized by Western Blot.
Results: PRG4 expression by chondrocytes near the articular surface was markedly decreased by IL-1a, stimulated by TGF-b1, and not
affected by IGF-I. The level of PRG4 accumulation in the culture medium was correlated with the number of chondrocytes expressing
PRG4. The amount of PRG4 bound at the articular surface was modulated by incubation in medium including FBS, but did not correlate
with levels of PRG4 secretion.
Conclusions: Cartilage secretion of PRG4 is highly regulated by certain cytokines and growth factors, in part through alteration of the number
of PRG4-secreting chondrocytes near the articular surface. The biochemical milieu may regulate the PRG4 content of synovial ﬂuid during
cartilage injury or repair.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage is a multifunctional tissue at the ends of
long bones that allows for smooth articulation within dia-
rthrodial joints1. Cartilage consists of three zones (super-
ﬁcial, middle, and deep), each with distinct matrix
structure and composition2,3 that impart specialized me-
chanical properties to these regions4,5. Chondrocytes of
the middle and deep zones synthesize aggrecan at high
rates, and thereby contribute to the ability of cartilage to
bear compressive load. The chondrocytes of the superﬁcial
zone exhibit a number of speciﬁc functions including the
synthesis and secretion of superﬁcial zone protein (SZP)6.
SZP is a w345 kDa protein present at the surface of
articular cartilage6, and in synovial ﬂuid7, encoded for by
the proteoglycan 4 (PRG4) gene8.
PRG4 molecules play an important role in the lubrication
of articular cartilage by synovial ﬂuid9e14. In addition to en-
coding for SZP, the PRG4 gene encodes for a highly homol-
ogous protein termed lubricin15, a w220 kDa product of
synovial ﬁbroblasts originally isolated from synovial ﬂuid16.*Address correspondence and reprint requests to: Dr Robert L.
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90Mutations of the PRG4 gene can cause camptodactyly-
arthropathy-coxa vara-pericarditis (CACP) disease in
humans17, which results in joint failure associated with
non-inﬂammatory synoviocyte hyperplasia and subintimal
ﬁbrosis of the synovial capsule18. Both SZP and lubricin
have boundary lubrication properties for native cartilage or
certain synthetic surfaces9e14. Since the Human Genome
Organization Gene Nomenclature Committee assigned
the name PRG4 for the gene (GenBank accession no.
AF056218 for bovine partial sequence and U70136 for com-
plete human sequence) encoding various immunoreactive
proteins8,17,19, including megakaryocyte stimulating factor,
we refer collectively these molecules, herein, as
PRG46,20. PRG4 therefore plays an important role in joint
mechanics.
In joint injury and arthritis, the synovial ﬂuid has impaired
friction-lowering lubrication qualities21,22, possibly due to
altered in vivo metabolism of PRG4 under regulation of
the altered cytokine environment. In vitro studies have
demonstrated cytokines transforming growth factor-beta 1
(TGF-b1) and interleukin-1 alpha (IL-1a), which are present
at elevated levels in joint injury and arthritis23, up-regulate
and down-regulate PRG4 secretion into culture medium, re-
spectively, from superﬁcial zone chondrocytes in explant
culture, as assessed by enzyme-linked immunosorbent as-
say (ELISA)24, and by chondrocytes in agarose culture, as
assessed by Western Blot19. Preliminary studies have
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lated in a similar manner, using immunohistochemistry to
identify chondrocytes secreting PRG424. Insulin like growth
factor I (IGF-I), a potent physiological regulator of proteogly-
can metabolism by chondrocytes25,26, may also regulate
PRG4 metabolism. These cytokines may also modulate
the amount of PRG4 bound at the surface of articular carti-
lage, where it is positioned to impart boundary lubrication
function27. The relationships between the amount of
PRG4 bound at the articular surface, PRG4 expression
within chondrocytes at or near the articular surface, and
PRG4 secretion from cartilage explants are unknown. Col-
lectively, these features of cartilage PRG4 metabolism
may be key aspects of PRG4 lubrication function.
The objectives of this study were therefore to determine
(1) if IL-1a, IGF-I, and TGF-b1 regulate PRG4 metabolism
in articular cartilage, in terms of chondrocytes expressing
PRG4 and PRG4 bound at the articular surface, and (2) if
these features of cartilage PRG4 metabolism correlate
with its secretion.MethodsMATERIALSMaterials for tissue harvest and culture were obtained as
described previously24,28. Recombinant human IL-1a, por-
cine TGF-b1, and recombinant human IGF-I were obtained
from R&D Systems (Minneapolis, MN).CARTILAGE EXPLANT HARVEST AND CULTURECartilage explants were harvested and cultured as
described previously24. Brieﬂy, osteochondral cores were
harvested from the patellofemoral groove of immature
(1e3 week old) bovine stiﬂe joints. These cores were cut
in a sledge microtome to obtain slices (0.3 mm thick) con-
taining the superﬁcial zone, with the articular surface intact.
These slices of cartilage were then punched into smaller
3 mm diameter disks. Disks were then incubated for 6
days in a basal medium (Dulbecco’s modiﬁed Eagle me-
dium [DMEM], 10 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid [HEPES] buffer, 0.1 mM nonessential
amino acids, 0.4 mM L-proline, 2 mM L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml ampho-
tericin B) at 37C in an atmosphere of 5% CO2, supple-
mented with 25 mg/ml ascorbic acid, 0.01% bovine serum
albumin (FBS) or 10% fetal bovine serum (þFBS), as
well as 10 ng/ml IL-1a, 300 ng/ml IGF-I, or 10 ng/ml TGF-b1.
Every 2 days, medium (0.360 ml per disk) was replaced, and
the spent medium was collected for subsequent analysis.PRG4 ANALYSIS IN CARTILAGE EXPLANTSPRG4 immunolocalization
PRG4 expression within chondrocytes of cartilage disks
was visualized by immunohistochemistry (IHC) using the
monoclonal antibody (mAb) 3A4 (a gift from Dr Bruce Cater-
son29), as described previously24. Brieﬂy, after 6 days of
culture, disks were incubated overnight in medium supple-
mented with 0.1 mM monensin, and then rinsed with phos-
phate buffered saline (PBS). Five micrometer thick
cryosections were prepared, reacted with mAb 3A4, and de-
tected with a peroxidase-based system. As negative con-
trols, some samples were probed with a non-speciﬁc
isotype-matched (IgG) antibody. The stained sampleswere viewed and documented by photomicroscopy to iden-
tify immunoreactive cells, indicating synthesis of PRG4.
The depth-associated variation in chondrocyte PRG4 ex-
pression was determined from these micrographs, essen-
tially as described previously30. Brieﬂy, a representative
740 mm wide 300 mm deep region of each section was an-
alyzed using a customprogramwritten inMatlab 6.5 software
(The Mathworks, Inc.). Chondrocytes expressing PRG4
(PRG4þ) were identiﬁedmanually by one reader, in a blinded
manner. (This was conﬁrmed as being reasonably indepen-
dent of the reader in these studies since eight micrographs
were also read by a second reader, and the number of
PRG4þ cells identiﬁed were signiﬁcantly correlated to those
identiﬁed by the ﬁrst reader,P< 0.001 andR2¼ 0.97.) Then,
the total number of PRG4þ cells, and the number of PRG4þ
cells as a function of depth from the articular surface were
counted. Results are presented as the number of PRG4þ
cells in successive 50 mm bins below the articular surface.
The total number of cells counted in each section was
300 98 (mean standard deviation (SD).
PRG4 surface concentration
PRG4 bound to the articular surface of freshly isolated
disks, and those cultured for 6 days, was determined by ex-
traction and ELISA, as described previously31. Brieﬂy, four
3 mm disks were nutated in 0.4 ml of 4 M GuHCl, 0.02 M
Tris, pH 8.2 containing protease inhibitors (0.005 M benza-
midine HCl, 0.01 M N-ethylmaleimide, 0.005 M disodium
ethylenediamine tetraacetic acid , and 0.001 M phenylme-
thylsulfonylﬂuoride) for 24 h. Portions (200 ml) of extracts
or puriﬁed bovine standards6 were then applied to a nitrocel-
lulose membrane in a Bio-Dot apparatus (Bio-Rad, Hercu-
les, CA), blocked with 5% non-fat dry milk, incubated with
mAb 3A4, and then with an anti-mouse antibody conjugated
to horseradish peroxidase, with rinses in PBS between
each step. The sample areas were removed and reacted
with 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
(ABTS) substrate. Control studies, where a known amount
of PRG4 (in the form of medium conditioned by explants
containing the superﬁcial zone and quantiﬁed by ELISA)
was added to serial dilutions of sample extracts, indicated
the extracted cartilage components in samples caused neg-
ligible interference in this assay of PRG4 content. Amounts
of PRG4 were expressed as mg/cm2 area of articular sur-
face (since PRG4 has been immunolocalized at or near
the articular surface of intact disks, both freshly isolated
and cultured24.)PRG4 ANALYSIS OF SPENT CULTURE MEDIUMPRG4 secretion
PRG4 secreted into culture medium was quantiﬁed by
ELISA using mAb 3A4, as described previously28. Brieﬂy,
medium samples pooled from the 6 day culture were diluted
serially, adsorbed to ELISA plates, and then reacted with
mAb 3A4, horseradish peroxidase-conjugated secondary
antibody, and ABTS substrate, with three washes with
PBSþ 0.1% Tween between each step. PRG4 levels
were calculated using puriﬁed bovine standards29.
Western Blot
PRG4 in spent culture medium samples, pooled from the 6
day culture, was characterized by Western Blot, essentially
as described previously30. PRG4 was puriﬁed from equal
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matography with diethylaminoethyl (DEAE) Sepharose
gel, collecting the 0.3e0.6 M NaCl eluate, concentration
with a Centricon Plus 100 kDaMW cutoff ﬁlter, dialysis
against distilled water, and then lyophilization. Samples con-
taining the same amount of recovered dry mass (10 mg) for
each condition were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) on
a 3e8% gradient polyacrylamide gel, transferred to a polyvi-
nylidene diﬂuoride (PVDF) membrane, and probed with mAb
3A4, with ECL-Plus detection. Luminescence from the mem-
brane was digitized with a STORM 840 Imaging System
(Molecular Dynamics, Fairﬁeld, CT).STATISTICAL ANALYSISData are expressed as the mean S.E.M.. Effects of me-
dium components (FBS and cytokines) on PRG4 expres-
sion by chondrocytes were assessed by analysis of
variance (ANOVA) with depth as a repeated measure;
a square root transformation was applied to improve the
uniformity of variance amongst the experimental groups. Ef-
fects of medium components on PRG4 surface concentra-
tion were assessed by ANOVA, with Tukey’s post hoc
tests for comparisons between experimental groups. The
effect of culture on PRG4 surface concentration was also
assessed by ANOVA with Dunnett’s post hoc tests for com-
parisons to freshly isolated disks. Effects of medium compo-
nents on PRG4 secretion were assessed by ANOVA, after
a log transformation to improve uniformity of variance, with
Tukey’s post hoc tests. The relationships between the total
number of PRG4þ cells and PRG4 secretion, and PRG4
surface concentration and PRG4 secretion, were analyzed
by linear regression.ResultsPRG4 ANALYSIS IN CARTILAGE EXPLANTSPRG4 immunolocalization
PRG4 was localized differentially in cartilage disks, de-
pending on the culture conditions (Fig. 1). In verticalFig. 1. Effect of culture conditions on PRG4 presence and expression by
Disks were cultured in medium supplemented with 25 mg/ml ascorbic acid,
TGF-b1. PRG4 was probed with mAb 3A4 in disks after 6 daysections from all groups, PRG4 staining was evident at
the articular surface, and within chondrocytes near the artic-
ular surface. Control samples using the non-speciﬁc IgG pri-
mary antibody were appropriately PRG4 negative.
The total number of PRG4þ cells and depth-associated
variation in chondrocyte expression was modulated by cul-
ture condition (Fig. 2). The total number of PRG4þ cells
varied with cytokine treatment (P< 0.001), but not with
FBS (P¼ 0.78) or an interaction (P¼ 0.61). Samples incu-
bated without additives, i.e., without and with FBS, had
51 10 PRG4þ cells, which was similar to the number of
PRG4þ cells in samples treated with IGF-I (41 8,
P¼ 0.74). In comparison, samples treated with TGF-b1
had signiﬁcantly more (228 20, P< 0.001) PRG4þ cells,
and those treated with IL-1a had signiﬁcantly less (6 3,
P< 0.001). The number of PRG4þ cells also varied with
depth from the articular surface (P< 0.001), with signiﬁcant
interactions between depth and FBS or cytokines (each
P< 0.001). Untreated samples had many PRG4þ cells in
the top 200 mm and very few below 200 mm, in medium
FBS [Fig. 2(A)] and þFBS [Fig. 2(B)]. Samples treated
with IL-1a, IGF-I, TGF-b1 appeared to have less, similar,
and more PRG4þ cells, respectively, in the top 200 mm of
tissue compared to untreated samples. Additionally, sam-
ples treated with TGF-b1 consistently had PRG4þ cells be-
low a depth of 200 mm, whereas all other groups did not.
PRG4 surface concentration
The amount of PRG4 bound to the articular surface of disks
at the end of the culture period varied with FBS (P< 0.01), but
not with cytokine (P¼ 0.92), and without an interaction effect
(P¼ 0.08, Fig. 3). Samples incubated in medium without
FBS had 0.72 0.05 mg/cm2 PRG4, which was similar to
the amount bound to samples treated with IL-1a,
0.49 0.07 mg/cm2 (P¼ 0.51), IGF-I, 0.65 0.11 mg/cm2
(P¼ 0.99), and TGF-b1, 0.52 0.08 mg/cm2 (P¼ 0.66).
These samples did, however, have signiﬁcantly more PRG4
bound than those samples incubated in medium þFBS
(0.33 0.12 mg/cm2, P< 0.05). Samples incubated in me-
dium þFBS had bound PRG4 levels that were unaffected
(P¼ 0.96e1.00) by additional treatment with IL-1a
(0.46 0.03 mg/cm2), IGF-I (0.32 0.10 mg/cm2), or TGF-b1chondrocytes in cartilage explants containing the superﬁcial zone.
10% FBS, as well as 10 ng/ml IL-1a, 300 ng/ml IGF-I, or 10 ng/ml
s of culture. A non-speciﬁc IgG was used for the control.
Fig. 2. Effect of culture conditions on depth-dependent PRG4
expression by chondrocytes in cartilage explants containing the
superﬁcial zone, represented as cells per area. PRG4 was probed
with mAb 3A4 in disks after 6 days of culture. Data are mean S.E.M.
(n¼ 6e7). ***¼P< 0.001.
Fig. 3. Effect of culture conditions on the amount of PRG4 bound to
the surface of cartilage explants containing the superﬁcial zone
af ter 6 days of cul ture. Data are mean  S.E .M. (n ¼ 5) .
*¼P< 0.05; D[ P< 0.05, DD[ P< 0.01, DDD[ P< 0.001
compared to day 0.
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articular surface of freshly isolated samples (Day 0),
0.85 0.08 mg/cm2, was signiﬁcantly more than the amount
bound to the surface of samples incubated in medium FBS
and treated with IL-1a or TGF-b1 (P< 0.05), and also more
than every sample group incubated in medium þFBS
(P< 0.001e0.05).PRG4 ANALYSIS OF SPENT CULTURE MEDIUMFig. 4. Effect of culture conditions on PRG4 secretion by chondro-
cytes in cartilage explants containing the superﬁcial zone. PRG4
secretion rates are shown averaged over 6 days of culture. Shaded
regions indicate levels at or below assay sensitivity. Data are
mean S.E.M. (n¼ 8). *¼P< 0.05.PRG4 secretion
The average rate of PRG4 secretion over the 6 days of
culture varied with FBS (P< 0.01) and cytokine treatment
(P< 0.001), without an interaction effect (P¼ 0.60)
(Fig. 4). Samples incubated in medium FBS secreted
1.3 0.3 mg/cm2/day, which was similar to the amount se-
creted by samples treated with IGF-I (1.9 0.7 mg/cm2/
day, P¼ 1.0). Compared to untreated samples during incu-
bation, those treated with TGF-b1 secreted signiﬁcantly
more PRG4 (65 18 mg/cm2/day, P< 0.01), while those
treated with IL-1a secreted signiﬁcantly less (0.05
0.04 mg/cm2/day, P< 0.001). For samples incubated in
medium þFBS, the trends in regulation of PRG4 secretionwere similar, although the rates were signiﬁcantly higher.
Samples incubated with FBS secreted 4.3 1.3 mg/cm2/
day, while those additionally treated with IL-1a, IGF-I,
TGF-b1 secreted 0.21 0.05 mg/cm2/day, 4.8 0.8 mg/
cm2/day, and 124 15 mg/cm2/day, respectively.
Western Blot
A major band immunoreactive with mAb 3A4 appeared at
an apparent molecular weight of w345 kDa in all samples,
Fig. 5. Western Blot of PRG4 secreted by chondrocytes in cartilage
explants containing the superﬁcial zone under various culture con-
ditions probed with mAb 3A4 after separation on a 3e8% gradient
polyacrylamide gel.
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peared slightly above, and another slightly below the
w345 kDa band (Fig. 5). Considering the relative proportion
of sample applied to each lane, the differences in band in-
tensities between the groups (Fig. 5) appeared consistent
with the differences in secretion observed by ELISA (Fig. 4).PRG4 EXPRESSION CORRELATIONSFig. 6. Correlation of PRG4 secretion by chondrocytes in cartilage
explants containing the superﬁcial zone over 6 days of culture to
(A) the total PRG4þ cells per area in the cartilage explants, and
(B) the amount of PRG4 bound at the surface of the cartilage ex-The average rate of PRG4 secretion over the 6-day cul-
ture was regressed linearly with the total number of
PRG4þ cells and the PRG4 bound to the articular surface
at the end of the culture period (Fig. 6). The average rate
of PRG4 secretion showed a strong correlation with the total
number of PRG4þ cells [R2¼ 0.61, P< 0.001, Fig. 6(A)].
Conversely, PRG4 secretion did not correlate with the
amount of PRG4 bound to the articular surface [P¼ 0.75,
Fig. 6(B)].plants, at the end of the culture duration. Shaded regions indicate
levels at or below assay sensitivity.Discussion
These results indicate that (1) PRG4 expression in
chondrocytes near the articular surface is highly regulated
by IL-1a and TGF-b1, and is strongly correlated with PRG4
secretion, and (2) PRG4 bound at the articular surface is
modulated by incubation in medium with FBS, in a way that
does not correlate with PRG4 secretion. IL-1a had an inhibi-
tory effect on PRG4 expression by chondrocytes, TGF-b1
had a stimulatory effect, whereas IGF-I had no detectable ef-
fect (Figs. 1and2). Theamount ofPRG4bound to thesurface
of cultured diskswas not signiﬁcantly altered by cytokine sup-
plementation, whereas incubation in medium þFBS did sig-
niﬁcantly reduce the amount of surface bound PRG4
compared to freshly isolated disks (Fig. 3). In all culture con-
ditions, the PRG4 secreted into the medium (Fig. 4), with an
apparent molecular weight (based on migration distance) at
w345 kDa on SDS-PAGE (Fig. 5). PRG4 secretioncorrelated strongly with PRG4 expression, but not the
amount of PRG4boundat thearticular surface (Fig. 6). These
results provide insight into chondrocyte metabolism of the
boundary lubricant, PRG4, under conditions relevant to
normal growth, homeostasis, and pathology of articular
cartilage.
Under particular culture conditions, this study assessed
PRG4metabolism quantitatively in terms of number of chon-
drocytes staining positively by IHC, the amount bound at the
articular surface and quantiﬁed in tissue extracts by ELISA
(since the relative IHC staining intensity may not be directly
related to the quantity of matrix-bound epitope), and that
present in the medium by ELISA. Any apparent effects of
IGF-I and TGF-b1 on surface bound PRG4 as assessed by
IHC could be related to altered cartilage matrix metabolism
of proteoglycans25,26,32, thereby possibly affecting surface
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0.1 mM monensin prior to IHC inhibited PRG4 secretion to
undetectable levels (<0.001 mg in 0.1 ml of medium28), sug-
gesting that essentially all of the synthesized PRG4 was
trapped within the chondrocytes. The accumulation of
PRG4 molecules in culture medium represents molecules
predominantly synthesized, since the amount present at
the articular surface before and after culture was much
less, as described previously24,28,30. The reported secretion
levels could be slight underestimations of the total synthesis,
under certain conditions where secretion rates are relatively
low, depending on the as of yet unknown partition coefﬁ-
cients of PRG4 in cartilage. The serial dilution curves of me-
dium samples obtained by ELISA for PRG4 were similar,
irrespective of growth factor or cytokine supplementation, in-
dicating non-PRG4 proteins or glycosaminoglycans in the
samples did not interfere with the assay for PRG4 content.
The concentration of TGF-b1 and IL-1a (10 ng/ml) was cho-
sen because their respective stimulatory and inhibitory ef-
fects on PRG4 secretion by chondrocytes in explants
containing the superﬁcial zone was previously shown to be
dose-dependent and plateaued at 10 ng/ml24. Similarly, the
concentration of IGF-I (300 ng/ml) was chosen because
the dose-dependent stimulatory effect on proteoglycan syn-
thesis plateaued at 30e300 ng/ml26. Physiological levels
have been reported to range fromw4 to 10 ng/ml in arthritic
human SF33 for TGF-b1, fromw45 to 103 ng/ml in osteoar-
thritic human SF34,35 for IGF-I, and increase after severe
acute injury in horse SF36 to levels >0.005 ng/ml for IL-1.
Therefore the concentrations used in this study are in the
range of pathophysiological levels. Immature articular bo-
vine cartilage was used in this study since its expression of
PRG4 is known to bemechanically regulated30,37; its biosyn-
thetic response to biochemical stimuli may be more vigorous
than that of adult cartilage, since its density of cells is higher
than that of mature tissue38. Three-dimensional imaging
analysis39 of the tissue used here has shown a thin layer
(w50 mm) of ﬂattened cells typical of the superﬁcial zone of
cartilage, followed by spheroidal cells in small groups, typical
of the middle zone; the classical deep zone may not be pres-
ent until later in the development process40,41. Although the
boundary between thesemorphologically distinct zones can-
not be sharply deﬁned, the morphology of cells, structure of
the extracellular matrix, and the PRG4þ phenotype (Fig. 1)
contained in the region of tissue used here (top w300 mm)
suggest that a classical superﬁcial zone exists in the imma-
ture tissue. Additionally, the up-regulation of PRG4 expres-
sion by chondrocytes in immature cartilage explants
containing the top w300 mm by chemical (TGF-b1)24 and
mechanical (shear)30 stimuli, but not in explants without
the top w300 mm, also suggests a superﬁcial zone exists
in immature tissue.
The results of this study agree with and extend previous
studies on the regulatory effects of TGF-b1 and IL-1a on
PRG4 secretion by chondrocytes. TGF-b1 and IL-1a have
been shown to qualitatively up- and down-regulate, respec-
tively, chondrocyte secretion of PRG4 into culture medium
by Flannery et al.19. Chondrocytes from the superﬁcial zone
of bovine calf articular cartilage were cultured in agarose
for 10 days with DMEMþ 5% FBS, alone, or with 2 ng/ml
TGF-b1 or 10 ng/ml IL-a. Western Blots of the conditioned
culture medium probed with mAb 3A4 indicated that TGF-
b1 stimulatedw345 kDa PRG4 secretion while IL-1a mark-
edly inhibited secretion. In a preliminary study24, we found
a dose-dependent (0.1, 1, and 10 ng/ml were examined)
stimulatory and inhibitory effect of TGF-b1 and IL-1a,
respectively, on PRG4 secretion into culture medium bychondrocytes in explants containing the superﬁcial zone,
both in the presence and absence of 10% FBS. Additionally,
we demonstrated the time course of alteration of PRG4 se-
cretion was fairly rapid, with differences in PRG4 secretion
clearly distinguishable after 2 days of culture with 10 ng/ml
of TGF-b1 or IL-1a, and changed gradually in subsequent
days (days 2e4 and 4e6). In the present study, the effects
of TGF-b1 and IL-1a at 10 ng/ml on PRG4 secretion by chon-
drocytes in explants containing the superﬁcial zone were
conﬁrmed. Future studies may address whether regulatory
effects are at the transcriptional, translational, or post-
translational level. Additionally, Western Blots of the
conditioned culture medium probed with mAb 3A4 indicated
the secreted PRG4 had an apparent molecular weight at or
nearw345 kDa (Fig. 5). This is consistent with several previ-
ous studies where PRG4 prepared frommedium conditioned
by superﬁcial zone chondrocytes was characterized using
similar methods of electrophoresis on SDS-PAGE gradient
gels6,19,29. Additionally, the 3e8% polyacrylamide gels
used here provided resolving capacity for high molecular
weight molecules; some variations in migration distance
near the apparent molecular weight of w345 kDa was evi-
dent, in particular with samples treated with TGF-b1 where
two immunoreactive bands were evident. The details of the
structural alterations of PRG4 secreted under TGF-b1 stimu-
lation, and their potential function signiﬁcance, remain to
be determined. The presence of an immunoreactive
w345 kDa band in the pooled conditioned medium supple-
mented with 10 ng/ml IL-1a is likely due to PRG4 secreted
early on in the culture media before IL-1a essentially abol-
ished PRG4 secretion. Other studies have also reported
the inclusion of ascorbic acid in culturemedia28, andmechan-
ical stimuli in the form of dynamic shear30, up-regulate PRG4
secretion by chondrocytes in explants. Collectively, these
results support the hypothesis that chemo-mechanical
processes govern chondrocyte metabolism42, speciﬁcally
secretion of PRG4, within articular cartilage.
Somewhat surprisingly, IGF-I, which stimulates proteogly-
can synthesis in articular cartilage26, did not modulate PRG4
secretion by chondrocytes in explants containing the superﬁ-
cial zone of articular cartilage. These results were different
than those reported in Flannery et al.19, which, found super-
ﬁcial zone chondrocytes in agarose culture with 30 ng/ml
IGF-I to secrete PRG4 to a similar (i.e., stimulatory) level as
with 10 ng/ml TGF-b1. In the present study, IGF-I at 300 ng/
ml had no detectable effect on PRG4 secretion by chondro-
cytes in explants containing the superﬁcial zone, although it
did stimulate proteoglycan synthesis (data not shown), as de-
scribed previously26. In addition, no detectable effect on
PRG4 secretion was observed at 3 and 30 ng/ml IGF-I
(data not shown). Whether superphysiological concentra-
tions>300 ng/ml IGF-I34,35 have effects remains to be deter-
mined. This difference may be attributable to the different
culture systems used43, and suggests that cellecell or celle
matrix interactions in cartilage may have regulatory roles
together with IGF-I.
Themarked biochemical regulation of the number of chon-
drocytes expressing PRG4 within cartilage is a major new
ﬁnding in the present study. Regulation by TGF-b1 and
IL-1a of chondrocyte expression of PRG4 near the articular
surface paralleled effects on secretion. The quantitative
analysis (Fig. 2) indicated that TGF-b1 and IL-1a up- and
down-regulate, respectively, the total number of PRG4þ
chondrocytes in cartilage explants containing the superﬁcial
zone. Therefore, not only does TGF-b1 increase the number
of PRG4þ chondrocytes, but also the apparent secretion rate
of each individual PRG4þ chondrocyte as well (since
96 T. A. Schmidt et al.: Differential regulation of PRG4 metabolismsecretion rates from cartilage disks increased w100-fold
(Fig. 4) whereas the total number of PRG4þ cells increased
only w5-fold). (Conversely, TGF-b1 and IL-1a appeared to
have a similar suppressive effect, in the absence of FBS,
on the amount of surface bound PRG4 (Fig. 3).) Dynamic
shear has also been shown to increase the total number of
PRG4þ chondrocytes in cartilage explants containing the
superﬁcial zone30. Collectively, these results broaden the
concept that chemo-mechanical processes govern chondro-
cyte metabolism of PRG4 within articular cartilage to include
both secretion and chondrocyte expression. Such chemo-
mechanical factors altering the depth from the articular
surface to which chondrocytes express PRG4, e.g., below
a depth of 200 mm, where chondrocyte do not normally
express PRG4 (Fig. 2 and in previous studies6,30) may com-
plicate the use of PRG4 synthesis as a phenotypic marker for
chondrocytes of the superﬁcial zone6,19. This would be espe-
cially so under pathophysiological conditions where the
chemo-mechanical milieu may be altered. Such altered or
enhanced chondrocyte expression of PRG4 may be part of
a feedback mechanism within articular cartilage, or a repair
type response of chondrocytes, in conditions where the
biochemo-mechanical milieu is altered.
The accumulations of PRG4within synovial ﬂuid and at the
articular surface, are likely key functional determinants of
PRG4’s boundary lubricating ability. PRG4 synthesis and se-
cretion by chondrocytes could signiﬁcantly contribute to the
concentration of PRG4 within synovial ﬂuid, in both homeo-
static and pathological conditions where physiological regu-
lators are present23. Although the amount of PRG4 bound
to the surface does not appear to correlate with secretion
rates, previous studies suggest surface boundPRG4 can ex-
changewith endogenousPRG4 in synovial ﬂuid44, especially
under the inﬂuenceofmechanical perturbation27,30. Clariﬁca-
tion of the spatial and temporal aspects of PRG4metabolism
within the joint, particularly at the articular surface, would
further the understanding of PRG4’s contribution to the low-
friction properties of articular cartilage, and possibly lead to
treatments to prevent loss of this function. More remains to
be determined about the processing, and the potentially addi-
tional or alternative functions of various PRG4 molecules of
different molecular weights9,10,19,30,45. Additional studies, in-
cluding further puriﬁcation and analysis of tissue andmedium
samples, may also clarify the basis for, and functional signif-
icance of, various PRG4 molecules, both secreted and pres-
ent at the articular surface, of different molecular weights.
Finally, the combination of chemical and mechanical factors
to stimulate PRG4 expression in chondrocytes near the
articular surfacemay be useful for creating tissue engineered
cartilage from isolated sub-populations46 with a surface that
is bioactive and functional in lubrication.Acknowledgments
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